Preview

Трансляционная медицина

Расширенный поиск

Экспериментальные модели изучения механизмов острой реакции трансплантат против хозяина (РтПх) на грызунах

https://doi.org/10.18705/2311-4495-2015-0-2-3-90-97

Полный текст:

Аннотация

Трансплантация гемопоэтических стволовых клеток - необходимая, и подчас единственная возможность излечения для многих пациентов с онкогематологическими заболеваниями. Современное развитие медицинских технологий всё больше расширяет спектр показаний к аллогенной трансплантации ГСК. Наряду с успехами в проведении трансплантаций остаются нерешенными ряд вопросов, касающихся осложнений после трансплантации. Одним из основных осложнений при аллогенной ТГСК является развитие имунного конфликта между клетками донора и тканями реципиента, получившего название реакции трансплантат против хозяина (РТПХ). Ключевые исследования механизмов РТПХ проводятся на модельных животных, в первую очередь на трансгенных мышах. Данный обзор посвящен обзору исследовательских моделей острой РТПХ, использование которых позволяет расширить знания о патогененезе этого явления и исследовать новые терапевтические схемы.

Об авторах

Павел Андреевич Бутылин
Федеральное государственное бюджетное учреждение «Северо-Западный федеральный медицинский исследовательский центр»
Россия


Ренат Шамилевич Бадаев
Федеральное государственное бюджетное учреждение «Северо-Западный федеральный медицинский исследовательский центр»
Россия


Дмитрий Васильевич Моторин
Федеральное государственное бюджетное учреждение «Северо-Западный федеральный медицинский исследовательский центр»
Россия


Список литературы

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006 Apr 27;354(17):1813-26.

2. Watt FM, Driskell RR. The therapeutic potential of stem cells. Philos Trans R SocLond B Biol Sci. 2010 Jan 12;365 (1537):155-163.

3. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM; IBMTR Statistical Center of the International Bone Marrow Transplant Registry, Medical College of Wisconcin, Milwaukee, WI, USA; EBMT, Kiel, Germany. Peripheral blood stem cell donation: an analysis from the International Bone Marrow TransplantRegistry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT)databases. Bone Marrow Transplant. 2001 Apr;27(7):689-692.

4. Uccelli A, Prockop DJ. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? CurrOpinImmunol. 2010 Dec;22(6):768-774.

5. Dazzi F, Krampera M. Mesenchymal stem cells and autoimmune diseases. Best Pract Res ClinHaematol. 2011 Mar;24 (1):49-57.

6. Barcena A, Muench MO, Kapidzic M, Gormley M, Goldfien GA, Fisher SJ. Human placenta and chorion: potential additional sources of hematopoietic stem cells for transplantation. Transfusion. 2011 Nov;51

7. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med. 2013 Jan;2(1):25-32.

8. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. BoneMarrow Transplant. 2014 Feb;49 (2):168-173.

9. Charles A Janeway, Jr, Paul Travers, Mark Walport, and Mark J Shlomchik. Immunobiology, 7th edition, The Immune System in Health and Disease, Garland Science; 2007.7th ed. ISBN 0-8153-4101-6.

10. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood. 2005 Jun;105(11):4191-4199.

11. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21-78.

12. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994 Apr 15;83(8):2360-2367.

13. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines. Blood. 1997 Oct 15;90(8):3204-3213.

14. Frederick E Nestel, Kursteen S. Price, Thomas A. Seemayer. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med. Feb 1, 1992; 175(2): 405-413.

15. Shin O. S. and Harris J. B. Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD. Korean J Hematol. Jun 2011; 46 (2): 69-79.

16. PoltorakA1, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations inTlr4 Gene. Science. 1998 Dec 11;282(5396):2085-2088.

17. Cooke KR1, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001 Jun;107(12):1581-1589.

18. Chakraverty R1, Cóté D, Buchli J, Cotter P, Hsu R, Zhao G, Sachs T, Pitsillides CM, Bronson R, Means T, Lin C, Sykes M. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med. 2006 Aug 7;203 (8):2021-31. Epub 2006 Jul 31.

19. Taylor PA1, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH, Murphy WJ, Serody JS, Hemmi H, Akira S, Levy RB, Blazar BR. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008 Oct 15;112 (8):3508-3516

20. Landfried K1, Bataille F, Rogler G, Brenmoehl J, Kosovac K, Wolff D, Hilgendorf I, Hahn J, Edinger M, Hoffmann P, Obermeier F, Schoelmerich J, Andreesen R, Holler E. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. ClinExpImmunol. 2010 Jan;159 (1):87-92.

21. Shlomchik WD1, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells. Science. 1999 Jul 16;285(5426):412-5.

22. Sallusto F1, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 2002;4Suppl 3: S127-32. Epub 2002 May 9.

23. Ju XP1, Xu B, Xiao ZP, Li JY, Chen L, Lu SQ, Huang ZX. Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation. Bone Marrow Transplant. 2005 Jun;35(12):1179-86.

24. Coghill JM1, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011 Mar 24;117(12):3268-76. doi: 10.1182/blood-2010-12-290403. Epub 2011 Jan 18.

25. Li J1, Semple K, Suh WK, Liu C, Chen F, Blazar BR, Yu XZ. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. Biol Blood Marrow Transplant. 2011 Jul;17(7):962-9. doi: 10.1016/j.bbmt.2011.01.018. Epub 2011 Mar 27.

26. Amarnath S1, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, Riley JL, Levine BL, June CH, Fong T, Warner NL, Fowler DH. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 2010 Feb 2;8(2): e1000302.

27. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.

28. Iwasaki A, Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987, 2004.

29. Falzarano G, Krenger W, Snyder KM, et al: Suppression of B-cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-alpha in mice with acute graft-versus-host disease. Blood 87:2853, 1996.

30. Nestel FP, Greene RN, Kichian K, et al: Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: Release of intracellular iron and nitric oxidemediated cytostasis

31. Sprent J, Schaefer M, Korngold R. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD. J Immunol. 1990 Apr 15;144(8):2946-54.

32. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005 Mar 1;105(5):2227-34.

33. Bhamidipati PK, DiPersio JF, Stokerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs andpost-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant. 2014 Aug;49(8):1124-6

34. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell. 1991 Apr 19;65(2):319-31.

35. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991 Apr 19;65 (2):305-17.

36. Shibaki A, Sato A, Vogel JC, Miyagawa F, Katz SI. Induction of GVHD-like skin disease by passively transferred CD8 (+) T-cell receptor transgenic T cells into keratin 14-ovalbumin transgenic mice. J Invest Dermatol. 2004 Jul;123(1):109-15.

37. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. 2003 May 5;197(9):1141-51.

38. Miyagawa F, Tagaya Y, Kim BS, Patel HJ, Ishida K, Ohteki T, Waldmann TA, Katz SI. IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease. J Immunol. 2008 Jul 15;181(2):1109-19.

39. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, Yu XZ. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010 Feb;16 (2):170-8.

40. Cheng H, Tian J, Li Z, Zeng L, Pan B, Song G, Chen W, Xu K. TH17 cells are critical for skin-specific pathological injury in acute graft-versus-host disease. Transplant Proc. 2012 Jun;44 (5):1412-8.

41. Villarroel VA, Okiyama N, Tsuji G, Linton JT, Katz SI. CXCR3-mediated skin homing of autoreactive CD8 T cells is a key determinant in murine graft-versus-host disease. J Invest Dermatol. 2014 Jun;134(6):1552-60

42. Malynn BA, Blackwell TK, Fulop GM, Rathbun GA, Furley AJ, Ferrier P, Heinke LB, Phillips RA, Yancopoulos GD, Alt FW. The scid defect affects the final step of the immunoglobulin VDJ recombinase mechanism. Cell. 1988 Aug 12;54(4):453-60.

43. Berney T, Molano RD, Pileggi A, Cattan P, Li H, Ricordi C, Inverardi L. Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes. Transplantation. 2001 Jul 15;72(1):133-40.

44. Greiner DL, Hesselton RA, Shultz LD. SCID mouse models of human stem cell engraftment. Stem Cells. 1998;16 (3):166-77.

45. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL, Handgretinger R. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005 May 15;174 (10):6477-89.

46. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010 Jul 15;116(2):193-200. doi: 10.1182/blood-2010-02-271841.

47. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain (null) mice. Blood. 2005 Sep 1;106(5):1565-73.

48. van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weij er K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood. 2003 Oct 1;102(7):2522-31.

49. Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, Schweitzer IB, Rajan TV, Gott B, Roopenian DC, Shultz LD. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol. 1997 Apr 15;158(8):3578-86.

50. Katano I, Ito R, Eto T, Aiso S, Ito M. Immunodeficient NOD-scid IL-2Rγ (null)mice do not display T and B cell leakiness. Exp Anim. 2011;60(2):181-6.

51. Büchner SM, Sliva K, Bonig H, Völker I, Waibler Z, Kirberg J, Schnierle BS. Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells. ClinExpImmunol. 2013 Aug;173(2):355-64.

52. Suzuki M, Takahashi T, Katano I, Ito R, Ito M, Harigae H, Ishii N, Sugamura K. Induction of human humoral immune responses in a novel HLA-DR-expressing transgenic NOD/Shiscid/ycnull mouse. IntImmunol. 2012 Apr;24(4):243-52.

53. Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, Eto T, Ito M. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation. 2009 Jun 15;87(11):1654-8.

54. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007 Feb;7 (2):118-30.

55. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant. 2003 May;9(5):292-303.

56. King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD, Greiner DL. Human peripheral blood leucocyte non-obese diabetic-severe combine d immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. ClinExpImmunol. 2009 Jul;157(1):104-18.

57. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech. 2011 May;4(3):318-33.

58. Hogenes MC, van Dorp S, van Kuik J, Monteiro FR, terHoeve N, van Dijk MR, Martens AC, de Weger RA. Histological assessment of the sclerotic graft-versus-host response in the humanized RAG2-/-yc-/- mouse model. BiolBlood Marrow Transplant. 2012 Jul;18(7):1023-35.


Для цитирования:


Бутылин П.А., Бадаев Р.Ш., Моторин Д.В. Экспериментальные модели изучения механизмов острой реакции трансплантат против хозяина (РтПх) на грызунах. Трансляционная медицина. 2015;(2-3):90-97. https://doi.org/10.18705/2311-4495-2015-0-2-3-90-97

For citation:


Butylin P., Badaev R..., Motorin D... Review of experimental animal models to study mechanisms of acute graft versus host disease (GVHD). Translational Medicine. 2015;(2-3):90-97. (In Russ.) https://doi.org/10.18705/2311-4495-2015-0-2-3-90-97

Просмотров: 72


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2311-4495 (Print)
ISSN 2410-5155 (Online)